Benicar, known generically as olmesartan medoxomil, is a prescription medication belonging to the class of drugs called angiotensin receptor blockers. These medications are widely used for the treatment of high blood pressure, also known as hypertension. Olmesartan works by blocking the action of angiotensin II, a natural substance in the body that causes blood vessels to narrow. By preventing this narrowing, olmesartan helps blood vessels relax and widen, which allows blood to flow more easily and reduces blood pressure. The medication is available in tablet form and is typically taken once daily. Benicar is also available in a combination product with hydrochlorothiazide, a diuretic, for patients who need additional blood pressure control. This comprehensive guide will explore all aspects of Benicar, including its mechanism of action, primary uses, dosing guidelines, potential side effects, drug interactions, and important safety considerations. Whether you are newly prescribed this medication or are considering it as a treatment option, this article provides the detailed information necessary to understand how Benicar works and what to expect during the course of therapy.
Understanding benicar and its mechanism of action
The pharmacological foundation of Benicar rests on its role as a selective angiotensin II type 1 receptor antagonist. To fully appreciate how this medication works, it is helpful to understand the renin angiotensin aldosterone system, which is a complex hormonal cascade that is important in regulating blood pressure, fluid balance, and electrolyte homeostasis throughout the body. When blood pressure drops, when sodium levels decrease, or when the sympathetic nervous system is activated, the kidneys release an enzyme called renin into the bloodstream. Renin then acts on angiotensinogen, a protein that is continuously produced by the liver and circulates in the blood, cleaving it to form angiotensin I, a relatively inactive peptide. The angiotensin converting enzyme, which is found primarily in the endothelial lining of blood vessels throughout the body, particularly in the lungs, then converts angiotensin I into angiotensin II. Angiotensin II is a potent vasoconstrictor that causes blood vessels to narrow and constrict, thereby increasing peripheral vascular resistance and raising blood pressure. Also, angiotensin II stimulates the adrenal glands to release aldosterone, a hormone that signals the kidneys to retain sodium and water while excreting potassium. This sodium and water retention further increases blood volume and blood pressure. Angiotensin II also promotes cellular growth and remodeling in the heart and blood vessels, contributes to oxidative stress and inflammation, and stimulates the release of other hormones that affect cardiovascular function. Olmesartan works by selectively and competitively blocking the angiotensin II type 1 receptor, which is the receptor subtype responsible for most of the harmful effects of angiotensin II. By occupying this receptor site, olmesartan prevents angiotensin II from binding and exerting its effects, even in the presence of high angiotensin II levels. This blockade leads to vasodilation and reduced peripheral vascular resistance, decreased aldosterone secretion with reduced sodium and water retention, and inhibition of the detrimental growth promoting and inflammatory effects of angiotensin II on the cardiovascular system. The result is a sustained reduction in blood pressure that persists throughout the 24 hour dosing interval with once daily administration. Unlike angiotensin converting enzyme inhibitors, which also reduce angiotensin II production but affect the breakdown of other peptides such as bradykinin, olmesartan does not affect bradykinin metabolism. This is clinically significant because the accumulation of bradykinin is thought to be responsible for the persistent dry cough that commonly occurs with angiotensin converting enzyme inhibitor therapy. Therefore, angiotensin receptor blockers like Benicar are often better tolerated and are a suitable alternative for patients who cannot tolerate angiotensin converting enzyme inhibitors due to cough. Olmesartan is a prodrug that is rapidly converted to its active metabolite, olmesartan, by esterases in the gastrointestinal tract and liver during absorption. This conversion is efficient and complete, ensuring reliable bioavailability. The active metabolite has a half life of approximately 10 to 15 hours, supporting once daily dosing, and it is primarily eliminated through the bile and feces, with minimal renal excretion. This biliary route of elimination is an advantage in patients with kidney impairment, as the drug does not accumulate in renal dysfunction.
Primary medical uses of benicar
The primary and most well established indication for Benicar is the treatment of hypertension, or high blood pressure, a condition that affects approximately one in three adults worldwide and is a major risk factor for cardiovascular disease, stroke, kidney disease, and other serious health conditions. Benicar is effective for lowering blood pressure in most patients with hypertension, and it can be used alone or in combination with other antihypertensive agents. The medication’s effectiveness in reducing blood pressure has been shown in numerous clinical trials involving patients with mild to moderate hypertension, and in patients with more severe hypertension when used in combination with other medications. Benicar is indicated for the treatment of hypertension in adults and in children aged six years and older. The blood pressure lowering effects of Benicar are dose dependent, with higher doses generally producing greater reductions in blood pressure. The medication reduces both systolic and diastolic blood pressure, and this reduction is maintained with long term therapy without the development of tolerance. The blood pressure reduction is consistent throughout the 24 hour dosing interval, including the early morning hours when cardiovascular events are most common. Benicar is also indicated for use in combination with other antihypertensive medications for patients who do not achieve adequate blood pressure control with monotherapy. It is particularly effective when combined with thiazide diuretics such as hydrochlorothiazide, and a fixed dose combination product is available that contains both olmesartan and hydrochlorothiazide in a single tablet. This combination provides additive blood pressure reduction because the two medications work through complementary mechanisms. In addition to its use in hypertension, olmesartan has been studied for its potential benefits in other conditions related to the renin angiotensin aldosterone system. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention study, known as the Roadmap study, investigated whether olmesartan could delay the onset of microalbuminuria, an early sign of kidney damage, in patients with type 2 diabetes who had normal kidney function at baseline. The study showed that olmesartan reduced the time to onset of microalbuminuria, suggesting a potential renoprotective effect. However, this study also raised some safety concerns regarding cardiovascular mortality, which have been subsequently evaluated and addressed. The Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial, or ORIENT study, evaluated olmesartan in patients with type 2 diabetes and established nephropathy. While the study did not meet its primary endpoint, it provided additional safety data and suggested possible benefits in certain subgroups. Current guidelines recommend angiotensin receptor blockers, including olmesartan, as a first line treatment option for hypertension, particularly in patients with compelling indications such as diabetes, chronic kidney disease with proteinuria, heart failure, and coronary artery disease. The medication is also recommended for patients who cannot tolerate angiotensin converting enzyme inhibitors due to cough or angioedema. Benicar may provide additional benefits beyond blood pressure reduction, including regression of left ventricular hypertrophy, improvement of endothelial function, and reduction of arterial stiffness, although these effects are not independent indications for use and are considered part of the medication’s overall cardiovascular protective effects.
Dosage and administration guidelines
Proper dosing of Benicar is essential for achieving optimal blood pressure control while minimizing the risk of adverse effects. The medication is available in tablet strengths of 5 milligrams, 20 milligrams, and 40 milligrams. For adults with hypertension who are not volume depleted, the recommended starting dose of Benicar is 20 milligrams taken once daily. The dose may be increased to 40 milligrams after two weeks of therapy if additional blood pressure reduction is needed. The maximum antihypertensive effect is typically achieved within two to four weeks of initiating therapy or adjusting the dose. For patients with more severe hypertension or those who require larger blood pressure reductions, a starting dose of 20 milligrams can be used with titration to 40 milligrams as needed. Some patients may achieve adequate blood pressure control with the 5 milligram dose, particularly those with mild hypertension or those who are at risk for hypotension. For pediatric patients aged six years and older, the recommended starting dose is 10 milligrams once daily for patients weighing 20 to less than 35 kilograms, and 20 milligrams once daily for patients weighing 35 kilograms or more. The dose may be increased after two weeks if needed, up to a maximum of 20 milligrams daily for patients weighing less than 35 kilograms and 40 milligrams daily for patients weighing 35 kilograms or more. Benicar can be taken with or without food, but it should be taken consistently with regard to meals to maintain reliable absorption. The tablet should be swallowed whole with a full glass of water and should not be crushed or chewed. If a patient misses a dose, they should take it as soon as they remember, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. Patients should never take two doses at the same time to make up for a missed dose. For patients switching to Benicar from another antihypertensive medication, the previous medication should be discontinued and Benicar started at the appropriate dose based on the patient’s blood pressure and clinical status. When adding Benicar to existing antihypertensive therapy, the same starting dose guidelines apply, and blood pressure should be monitored closely for excessive reduction. In patients who are volume depleted by diuretics, restricted sodium intake, or gastrointestinal fluid losses, the starting dose of Benicar should be reduced to 5 milligrams to minimize the risk of symptomatic hypotension. Volume depletion should be corrected before initiating therapy when possible. The maximum recommended dose is 40 milligrams daily for adults. Doses higher than this do not provide additional blood pressure reduction and may increase the risk of side effects. The combination product containing olmesartan and hydrochlorothiazide is available in several strengths, typically initiated after patients have been stabilized on the individual components or when monotherapy with one component is insufficient. When using the combination product, the doses of each component should be considered, and patients should not exceed the recommended maximum doses of either component. As with all antihypertensive medications, the effectiveness of Benicar should be assessed by regular blood pressure monitoring, both in the healthcare provider’s office and at home. Home blood pressure monitoring provides valuable information about blood pressure control throughout the day and can help guide dose adjustments. Patients should keep a log of their blood pressure readings and bring it to their healthcare appointments.
Side effects and adverse reactions
Benicar is generally well tolerated, with a side effect profile that is typical of angiotensin receptor blockers. The most common side effect in clinical trials was dizziness, which occurred in approximately 3 percent of patients taking olmesartan compared to 1 percent of patients taking placebo. This dizziness is usually mild and often resolves as the body adjusts to the medication. Rarely, it may indicate excessive blood pressure reduction, and the dose may need to be adjusted. Upper respiratory tract infections, including symptoms similar to the common cold, were reported in about 3 percent of patients, though this incidence was similar to placebo. Headache was reported in about 2 percent of patients, also similar to placebo. Gastrointestinal side effects including nausea, diarrhea, and dyspepsia have been reported but are uncommon. Back pain and joint pain occurred at similar rates to placebo in clinical trials. Hypotension, or excessively low blood pressure, can occur, particularly in patients who are volume depleted, those taking high doses of diuretics, and those with conditions that predispose to low blood pressure. Symptoms of hypotension include lightheadedness, fainting, and blurred vision. These symptoms are most common when starting therapy or increasing the dose and often improve with continued use. Orthostatic hypotension, a drop in blood pressure when standing up from a sitting or lying position, can also occur. Hyperkalemia, or elevated potassium levels, can occur because angiotensin receptor blockers reduce aldosterone production, which decreases potassium excretion. The risk of hyperkalemia is increased in patients with kidney impairment, diabetes, and in those taking potassium supplements, potassium sparing diuretics, or other medications that affect the renin angiotensin aldosterone system. Regular monitoring of potassium levels is recommended for patients at risk. Kidney function may be affected, particularly in patients with pre existing kidney disease, renal artery stenosis, or conditions that reduce kidney blood flow such as severe heart failure or volume depletion. A modest increase in serum creatinine is common when starting therapy and typically stabilizes over time. However, significant or persistent declines in kidney function require evaluation and possible dose adjustment or discontinuation. Angioedema is a rare but serious side effect that has been reported with olmesartan and other angiotensin receptor blockers. This condition involves swelling of the deeper layers of the skin, typically affecting the face, lips, tongue, and throat, and can be life threatening if the airway becomes compromised. Patients who develop any signs of angioedema should seek emergency medical care immediately. A unique concern that has been associated specifically with olmesartan is sprue like enteropathy, a gastrointestinal condition characterized by severe chronic diarrhea, weight loss, and intestinal inflammation that resembles celiac disease. This rare but serious side effect was identified through post marketing surveillance and has been described in a small number of patients taking olmesartan, sometimes after months or years of therapy. The condition typically resolves after discontinuing the medication. Patients who develop unexplained, prolonged, and severe diarrhea while taking Benicar should contact their healthcare provider. Other rare side effects include liver enzyme elevations, pancreatitis, and hematologic abnormalities such as neutropenia and agranulocytosis. Allergic reactions, including rash, urticaria, and anaphylaxis, can occur but are uncommon. Patients should be instructed to report any unusual or persistent symptoms to their healthcare provider and to seek immediate medical attention for symptoms of angioedema, severe hypotension, or significant changes in urinary output.
Drug interactions and contraindications
Understanding the drug interactions and contraindications of Benicar is essential for safe prescribing and use. The most significant drug interactions involve other agents that affect the renin angiotensin aldosterone system. Combining Benicar with angiotensin converting enzyme inhibitors or with the direct renin inhibitor aliskiren is generally not recommended due to an increased risk of hypotension, hyperkalemia, and kidney impairment. This dual blockade is specifically contraindicated in patients with diabetes or moderate to severe kidney impairment, as the risks outweigh any potential benefits in these populations. Potassium sparing diuretics, including spironolactone, eplerenone, triamterene, and amiloride, should be used with caution in combination with Benicar, as they can increase the risk of hyperkalemia. Potassium supplements and salt substitutes containing potassium should similarly be avoided unless specifically prescribed for documented hypokalemia. Regular monitoring of serum potassium is essential if these agents are used together. Nonsteroidal anti inflammatory drugs, including both selective cyclooxygenase 2 inhibitors and traditional nonselective agents such as ibuprofen, naproxen, and diclofenac, can reduce the antihypertensive effect of Benicar and may increase the risk of kidney impairment. The risk is particularly high in patients with pre existing kidney disease, elderly patients, and those who are volume depleted. Patients should use the lowest effective dose of nonsteroidal anti inflammatory drugs for the shortest duration possible and should maintain adequate hydration. Lithium levels can be increased by angiotensin receptor blockers, potentially leading to lithium toxicity. Patients taking lithium should have their lithium levels monitored closely when starting, stopping, or adjusting the dose of Benicar. Digoxin and warfarin have not been shown to interact with olmesartan in clinical studies, but patients taking these medications should still be monitored appropriately. Other antihypertensive medications, including beta blockers, calcium channel blockers, and diuretics, can have additive blood pressure lowering effects when combined with Benicar. This can be beneficial for blood pressure control but requires careful monitoring to prevent excessive hypotension. Colesevelam, a bile acid sequestrant used to lower cholesterol, can reduce the absorption of olmesartan and should be taken at least four hours apart from Benicar. Alcohol can potentiate the blood pressure lowering effects of Benicar and should be consumed in moderation, if at all. Regarding contraindications, Benicar should not be used in patients with a known hypersensitivity to olmesartan or any component of the formulation. Patients with a history of angioedema related to previous treatment with an angiotensin receptor blocker should not use Benicar. Pregnancy is an absolute contraindication for the use of Benicar. Medications that act directly on the renin angiotensin aldosterone system, including angiotensin receptor blockers, can cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and even fetal death when used during the second and third trimesters. Women of childbearing potential should use effective contraception while taking Benicar and should discontinue the medication immediately and contact their healthcare provider if they become pregnant. Bilateral renal artery stenosis or stenosis of the artery to a solitary functioning kidney is a relative contraindication, as angiotensin receptor blockers can cause acute kidney injury in these patients by reducing the pressure needed to maintain glomerular filtration. Severe kidney impairment, while not an absolute contraindication, requires careful monitoring and dose adjustment, and the medication should be used with caution in patients with a glomerular filtration rate below 30 milliliters per minute. Severe liver impairment has not been specifically studied with olmesartan, and caution is warranted in patients with advanced liver disease.
Special populations and monitoring requirements
Different patient populations require individualized considerations when using Benicar, and appropriate monitoring is essential to ensure safe and effective therapy. Elderly patients, those aged 65 years and older, may be more sensitive to the blood pressure lowering effects of olmesartan and are at increased risk for orthostatic hypotension, falls, and related injuries. Age related declines in kidney function may also affect the handling of the medication, though olmesartan’s biliary excretion makes it less dependent on kidney function than some other antihypertensive medications. Lower starting doses and more gradual dose titration are generally recommended for elderly patients, with careful monitoring of blood pressure, electrolytes, and kidney function. Patients with kidney impairment require special consideration because the renin angiotensin aldosterone system plays a critical role in maintaining kidney function. In patients with mild to moderate kidney impairment, Benicar can be used with appropriate monitoring, and it may provide beneficial renoprotective effects by reducing intraglomerular pressure and proteinuria. However, in patients with severe kidney impairment, particularly those with a glomerular filtration rate below 30 milliliters per minute, the medication should be used with caution, and the dose may need to be adjusted. Close monitoring of serum creatinine and potassium levels is essential in all patients with kidney impairment. Patients with liver impairment may have altered drug metabolism, but because olmesartan is primarily eliminated through the biliary route, liver impairment may actually affect drug clearance. However, specific dose adjustment guidelines for liver impairment are not well established, and caution is warranted. Patients with diabetes are at increased risk for hyperkalemia when taking angiotensin receptor blockers, particularly if they have diabetic nephropathy or are taking other medications that affect potassium levels. However, the benefits of angiotensin receptor blocker therapy in patients with diabetes, including blood pressure reduction and renoprotective effects, often outweigh these risks when appropriate monitoring is in place. The Roadmap study raised some questions about cardiovascular safety in patients with diabetes, but subsequent analyses have not confirmed a specific safety concern with olmesartan in this population. Patients with heart failure require careful monitoring of blood pressure, kidney function, and electrolytes when starting Benicar, as they may be more susceptible to hypotension and kidney impairment. However, angiotensin receptor blockers are recommended for the treatment of heart failure with reduced ejection fraction based on evidence from clinical trials. Patients of African descent may have a less robust blood pressure response to angiotensin receptor blocker monotherapy compared to other racial groups, likely due to differences in renin angiotensin aldosterone system activity and salt sensitivity. These patients often require higher doses or the addition of a diuretic to achieve adequate blood pressure control. However, the combination of an angiotensin receptor blocker with a thiazide diuretic is particularly effective in this population. Monitoring requirements for all patients taking Benicar include baseline and periodic measurement of blood pressure, serum electrolytes, particularly potassium, blood urea nitrogen, and serum creatinine. Blood pressure should be monitored at each healthcare visit and periodically at home using a validated device. Laboratory monitoring should be performed one to two weeks after initiating therapy or adjusting the dose, and then at regular intervals based on the patient’s clinical status and risk factors. Patients should be educated about the signs and symptoms of hyperkalemia, including muscle weakness, fatigue, palpitations, and paresthesias, and instructed to report these symptoms promptly. They should also be warned about the symptoms of hypotension and angioedema and advised to seek medical attention if these occur. Regular follow up visits are important to assess blood pressure control, monitor for side effects, adjust the dose as needed, and reinforce lifestyle modifications. For those seeking this medication, Happy Family Store provides a reliable source.
Lifestyle considerations and patient education
Patients taking Benicar can maximize the benefits of their treatment through appropriate lifestyle modifications and a thorough understanding of their medication. Dietary considerations play an important role in blood pressure management. The Dietary Approaches to Stop Hypertension diet is widely recommended for patients with hypertension. This diet emphasizes fruits, vegetables, whole grains, and low fat dairy products while limiting sodium, saturated fat, and added sugars. Sodium restriction is particularly important because it enhances the effectiveness of antihypertensive medications. Patients should aim for less than 2300 milligrams of sodium per day, with an ideal goal of 1500 milligrams per day for most adults with hypertension. Reading nutrition labels, choosing fresh over processed foods, and limiting restaurant meals can help achieve sodium reduction. Potassium intake should be consistent. While Benicar may cause a slight increase in potassium levels, patients do not need to avoid potassium rich foods. However, they should avoid large fluctuations in potassium intake and should not use potassium containing salt substitutes unless specifically approved by their healthcare provider. Adequate hydration is important for maintaining kidney function and preventing volume depletion. Patients should drink enough fluids to maintain normal urine output, but those with heart failure or kidney disease may have specific fluid restrictions that they should follow. During hot weather, vigorous exercise, or illness, additional fluid intake may be necessary to prevent dehydration. Alcohol consumption should be moderated. Heavy alcohol use can raise blood pressure and reduce the effectiveness of antihypertensive medications. Men should limit alcohol to two drinks per day, and women should limit to one drink per day. Regular physical activity is an important component of blood pressure management. The American Heart Association recommends at least 150 minutes of moderate intensity aerobic exercise per week, such as brisk walking, swimming, or cycling, or 75 minutes of vigorous intensity exercise per week. Resistance training two to three days per week can provide additional benefits. Patients should check with their healthcare provider before starting a new exercise program, particularly if they have other health conditions. Smoking cessation is one of the most important things a patient can do to improve their cardiovascular health. Smoking acutely raises blood pressure and heart rate, damages blood vessels, and dramatically increases the risk of heart attack and stroke. Patients who smoke should be offered counseling and pharmacotherapy to help them quit. Weight management is essential for blood pressure control. Excess weight contributes to hypertension through multiple mechanisms, including increased sympathetic nervous system activity, sodium retention, and insulin resistance. Even modest weight loss of 5 to 10 percent of body weight can produce meaningful reductions in blood pressure. A combination of dietary changes, increased physical activity, and behavioral modifications is the most effective approach to weight loss and maintenance. Stress management techniques, including mindfulness meditation, deep breathing exercises, yoga, or counseling, may help lower blood pressure and improve overall well being. Chronic stress can contribute to hypertension through activation of the sympathetic nervous system and unhealthy coping behaviors. Patients should inform all healthcare providers, including dentists and surgeons, that they are taking Benicar before any medical or dental procedures. The medication may need to be temporarily withheld before certain surgical procedures to prevent intraoperative hypotension. Anesthesiologists should be aware of the patient’s medication regimen. Travel considerations include carrying an adequate supply of medication in its original packaging, along with a copy of the prescription. Patients should plan for time zone changes and ensure they have enough medication for the duration of their trip, plus extra in case of unexpected delays. Patients traveling to hot climates should be particularly careful about hydration and should avoid excessive sun exposure. Women of childbearing potential should use effective contraception while taking Benicar and should immediately report any suspected pregnancy to their healthcare provider, as the medication can cause serious harm to the developing fetus. The medication should be stored at room temperature, away from moisture, heat, and light, and out of reach of children and pets.
Clinical studies and evidence base
The clinical development of Benicar was supported by a comprehensive program of preclinical and clinical studies that established its efficacy and safety for the treatment of hypertension. Numerous randomized, double blind, placebo controlled trials have demonstrated that olmesartan produces significant, dose dependent reductions in both systolic and diastolic blood pressure compared to placebo. In these studies, olmesartan 20 milligrams daily reduced systolic blood pressure by approximately 12 to 15 millimeters of mercury and diastolic blood pressure by approximately 8 to 10 millimeters of mercury compared to placebo. The 40 milligram dose provided additional reductions of about 2 to 3 millimeters of mercury for systolic and 1 to 2 millimeters of mercury for diastolic blood pressure. The antihypertensive effect of olmesartan was shown to be maintained throughout the 24 hour dosing interval, with a trough to peak ratio that supports once daily dosing. This consistent blood pressure control throughout the day is important because it provides protection during the early morning hours when blood pressure surges and cardiovascular events are most frequent. Comparative studies have shown that olmesartan is at least as effective as other angiotensin receptor blockers, including losartan, valsartan, and irbesartan, in reducing blood pressure. Some studies have suggested that olmesartan may provide slightly greater blood pressure reduction at the maximum recommended dose compared to some other agents in this class, though the clinical significance of these modest differences is debated. The Roadmap study was a large, multinational, randomized, double blind, placebo controlled trial that evaluated the effects of olmesartan on the development of microalbuminuria in patients with type 2 diabetes and normoalbuminuria. Over 4400 patients were enrolled and followed for a median of 3.2 years. The study showed that olmesartan reduced the time to onset of microalbuminuria by 23 percent compared to placebo, despite similar blood pressure control in both groups. This suggested a blood pressure independent renoprotective effect of olmesartan. However, an unexpected finding was a higher rate of cardiovascular death in the olmesartan group compared to the placebo group, though the total number of events was small and the difference was not statistically significant when adjusted for multiple comparisons. Subsequent analyses and additional studies have not confirmed this safety signal, and the Food and Drug Administration has not identified a specific cardiovascular safety concern with olmesartan. The ORIENT study evaluated olmesartan in patients with type 2 diabetes and overt nephropathy. While the study did not meet its primary composite endpoint of doubling of serum creatinine, end stage renal disease, or death, it suggested possible benefits in certain subgroups and provided important long term safety data. The Benicar product label includes information about the sprue like enteropathy that has been reported in a small number of patients. This condition was identified through post marketing surveillance and has been described in case reports and case series. The exact incidence is unknown but appears to be very rare. The mechanism is not well understood but may involve an immune mediated or direct toxic effect of olmesartan on the intestinal mucosa. The condition typically resolves within weeks of discontinuing the medication. The extensive clinical trial program and post marketing experience with olmesartan have provided a robust understanding of its safety profile. When used as directed for approved indications, the medication has a favorable benefit risk profile for the treatment of hypertension. Clinical practice guidelines from major organizations, including the American College of Cardiology, American Heart Association, European Society of Cardiology, and the International Society of Hypertension, recommend angiotensin receptor blockers as first line therapy for hypertension and as preferred agents in patients with compelling indications such as diabetes, chronic kidney disease, and heart failure.